Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features

Maria E. Figueroa, Bas J. Wouters, Lucy Skrabanek, Jacob Glass, Yushan Li, Claudia A J Erpelinck-Verschueren, Anton W. Langerak, Bob Löwenberg, Melissa Fazzari, John M. Greally, Peter J M Valk, Ari Melnick, Ruud Delwel

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Acute myeloid leukemia is a heterogeneous disease from the molecular and biologic standpoints, and even patients with a specific gene expression profile may present clinical and molecular heterogeneity. We studied the epigenetic profiles of a cohort of patients who shared a common gene expression profile but differed in that only half of them harbored mutations of the CEBPA locus, whereas the rest presented with silencing of this gene and coexpression of certain T-cell markers. DNA methylation studies revealed that these 2 groups of patients could be readily segregated in an unsupervised fashion based on their DNA methylation profiles alone. Furthermore, CEBPA silencing was associated with the presence of an aberrant DNA hypermethylation signature, which was not present in the CEBPA mutant group. This aberrant hypermethylation occurred more frequently at sites within CpG islands. CEBPA-silenced leukemias also displayed marked hypermethylation compared with normal CD34 + hematopoietic cells, whereas CEBPA mutant cases showed only mild changes in DNA methylation compared with these normal progenitors. Biologically, CEBPA-silenced leukemias presented with a decreased response to myeloid growth factors in vitro.

Original languageEnglish (US)
Pages (from-to)2795-2804
Number of pages10
JournalBlood
Volume113
Issue number12
DOIs
StatePublished - Mar 19 2009

Fingerprint

DNA Methylation
Acute Myeloid Leukemia
Epigenomics
Genes
Genome
Transcriptome
Gene expression
Leukemia
CpG Islands
T-cells
Gene Silencing
Intercellular Signaling Peptides and Proteins
T-Lymphocytes
Mutation
DNA

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Figueroa, M. E., Wouters, B. J., Skrabanek, L., Glass, J., Li, Y., Erpelinck-Verschueren, C. A. J., ... Delwel, R. (2009). Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood, 113(12), 2795-2804. https://doi.org/10.1182/blood-2008-08-172387

Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. / Figueroa, Maria E.; Wouters, Bas J.; Skrabanek, Lucy; Glass, Jacob; Li, Yushan; Erpelinck-Verschueren, Claudia A J; Langerak, Anton W.; Löwenberg, Bob; Fazzari, Melissa; Greally, John M.; Valk, Peter J M; Melnick, Ari; Delwel, Ruud.

In: Blood, Vol. 113, No. 12, 19.03.2009, p. 2795-2804.

Research output: Contribution to journalArticle

Figueroa, ME, Wouters, BJ, Skrabanek, L, Glass, J, Li, Y, Erpelinck-Verschueren, CAJ, Langerak, AW, Löwenberg, B, Fazzari, M, Greally, JM, Valk, PJM, Melnick, A & Delwel, R 2009, 'Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features', Blood, vol. 113, no. 12, pp. 2795-2804. https://doi.org/10.1182/blood-2008-08-172387
Figueroa ME, Wouters BJ, Skrabanek L, Glass J, Li Y, Erpelinck-Verschueren CAJ et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood. 2009 Mar 19;113(12):2795-2804. https://doi.org/10.1182/blood-2008-08-172387
Figueroa, Maria E. ; Wouters, Bas J. ; Skrabanek, Lucy ; Glass, Jacob ; Li, Yushan ; Erpelinck-Verschueren, Claudia A J ; Langerak, Anton W. ; Löwenberg, Bob ; Fazzari, Melissa ; Greally, John M. ; Valk, Peter J M ; Melnick, Ari ; Delwel, Ruud. / Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. In: Blood. 2009 ; Vol. 113, No. 12. pp. 2795-2804.
@article{2afb60798bde45d59fdf3d4ccd0fff5c,
title = "Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features",
abstract = "Acute myeloid leukemia is a heterogeneous disease from the molecular and biologic standpoints, and even patients with a specific gene expression profile may present clinical and molecular heterogeneity. We studied the epigenetic profiles of a cohort of patients who shared a common gene expression profile but differed in that only half of them harbored mutations of the CEBPA locus, whereas the rest presented with silencing of this gene and coexpression of certain T-cell markers. DNA methylation studies revealed that these 2 groups of patients could be readily segregated in an unsupervised fashion based on their DNA methylation profiles alone. Furthermore, CEBPA silencing was associated with the presence of an aberrant DNA hypermethylation signature, which was not present in the CEBPA mutant group. This aberrant hypermethylation occurred more frequently at sites within CpG islands. CEBPA-silenced leukemias also displayed marked hypermethylation compared with normal CD34 + hematopoietic cells, whereas CEBPA mutant cases showed only mild changes in DNA methylation compared with these normal progenitors. Biologically, CEBPA-silenced leukemias presented with a decreased response to myeloid growth factors in vitro.",
author = "Figueroa, {Maria E.} and Wouters, {Bas J.} and Lucy Skrabanek and Jacob Glass and Yushan Li and Erpelinck-Verschueren, {Claudia A J} and Langerak, {Anton W.} and Bob L{\"o}wenberg and Melissa Fazzari and Greally, {John M.} and Valk, {Peter J M} and Ari Melnick and Ruud Delwel",
year = "2009",
month = "3",
day = "19",
doi = "10.1182/blood-2008-08-172387",
language = "English (US)",
volume = "113",
pages = "2795--2804",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features

AU - Figueroa, Maria E.

AU - Wouters, Bas J.

AU - Skrabanek, Lucy

AU - Glass, Jacob

AU - Li, Yushan

AU - Erpelinck-Verschueren, Claudia A J

AU - Langerak, Anton W.

AU - Löwenberg, Bob

AU - Fazzari, Melissa

AU - Greally, John M.

AU - Valk, Peter J M

AU - Melnick, Ari

AU - Delwel, Ruud

PY - 2009/3/19

Y1 - 2009/3/19

N2 - Acute myeloid leukemia is a heterogeneous disease from the molecular and biologic standpoints, and even patients with a specific gene expression profile may present clinical and molecular heterogeneity. We studied the epigenetic profiles of a cohort of patients who shared a common gene expression profile but differed in that only half of them harbored mutations of the CEBPA locus, whereas the rest presented with silencing of this gene and coexpression of certain T-cell markers. DNA methylation studies revealed that these 2 groups of patients could be readily segregated in an unsupervised fashion based on their DNA methylation profiles alone. Furthermore, CEBPA silencing was associated with the presence of an aberrant DNA hypermethylation signature, which was not present in the CEBPA mutant group. This aberrant hypermethylation occurred more frequently at sites within CpG islands. CEBPA-silenced leukemias also displayed marked hypermethylation compared with normal CD34 + hematopoietic cells, whereas CEBPA mutant cases showed only mild changes in DNA methylation compared with these normal progenitors. Biologically, CEBPA-silenced leukemias presented with a decreased response to myeloid growth factors in vitro.

AB - Acute myeloid leukemia is a heterogeneous disease from the molecular and biologic standpoints, and even patients with a specific gene expression profile may present clinical and molecular heterogeneity. We studied the epigenetic profiles of a cohort of patients who shared a common gene expression profile but differed in that only half of them harbored mutations of the CEBPA locus, whereas the rest presented with silencing of this gene and coexpression of certain T-cell markers. DNA methylation studies revealed that these 2 groups of patients could be readily segregated in an unsupervised fashion based on their DNA methylation profiles alone. Furthermore, CEBPA silencing was associated with the presence of an aberrant DNA hypermethylation signature, which was not present in the CEBPA mutant group. This aberrant hypermethylation occurred more frequently at sites within CpG islands. CEBPA-silenced leukemias also displayed marked hypermethylation compared with normal CD34 + hematopoietic cells, whereas CEBPA mutant cases showed only mild changes in DNA methylation compared with these normal progenitors. Biologically, CEBPA-silenced leukemias presented with a decreased response to myeloid growth factors in vitro.

UR - http://www.scopus.com/inward/record.url?scp=63849197532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849197532&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-08-172387

DO - 10.1182/blood-2008-08-172387

M3 - Article

VL - 113

SP - 2795

EP - 2804

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -